Melinta Therapeutics, Inc. announced that Kevin Ferro resigned from the Board of Directors (the “Board”) and all committees of the Board of the Company effective August 5, 2019. Mr. Ferro's resignation did not involve any disagreement with the Company on any matter relating to the Company's operations, policies or practices. John H. Johnson resigned from his position as chief executive officer (“CEO”) of the Company effective August 5, 2019.

Mr. Johnson will serve as acting CEO for at least thirty days to work through the transition, including the search process and appointment of a permanent successor. Mr. Johnson also resigned from the Board and all committees of the Board effective August 5, 2019. Mr. Johnson's decision to resign is due to changes in the Company's circumstances and in order to pursue other opportunities and not because of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.

David Gill, a current member of the Board of the Company, has been named chairman of the Board, effective August 5, 2019.